Jazz Pharmaceuticals plc [JAZZ] stock prices are up 6.75% to $119.08 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The JAZZ shares have gain 8.23% over the last week, with a monthly amount glided 10.96%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on June 05, 2024, when Goldman initiated its Buy rating and assigned the stock a price target of $169. Previously, Robert W. Baird started tracking the stock with Outperform rating on January 03, 2024, and set its price target to $160. On November 27, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $135 on the stock. Raymond James started tracking the stock assigning a Mkt Perform rating. Goldman upgraded its rating to Buy for this stock on December 09, 2022, and downed its price target to $190. In a note dated June 14, 2022, UBS initiated an Buy rating and provided a target price of $194 on this stock.
The stock price of Jazz Pharmaceuticals plc [JAZZ] has been fluctuating between $99.06 and $134.48 over the past year. Currently, Wall Street analysts expect the stock to reach $200.23 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $119.08 at the most recent close of the market. An investor can expect a potential return of 68.15% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
The Jazz Pharmaceuticals plc [NASDAQ:JAZZ] reported sales of 3.99B for trailing twelve months, representing a surge of 8.52%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.1%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.12 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 116.15 points at the first support level, and at 113.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 121.62, and for the 2nd resistance point, it is at 124.17.
Ratios To Look Out For
It’s worth pointing out that Jazz Pharmaceuticals plc [NASDAQ:JAZZ]’s Current Ratio is 4.26. On the other hand, the Quick Ratio is 3.74, and the Cash Ratio is 2.15. Considering the valuation of this stock, the price to sales ratio is 1.84, the price to book ratio is 1.95 and price to earnings (TTM) ratio is 17.11.
Transactions by insiders
Recent insider trading involved COZADD BRUCE C, Chairman & CEO, that happened on Nov 01 ’24 when 1000.0 shares were sold. Officer, COZADD BRUCE C completed a deal on Nov 01 ’24 to buy 1000.0 shares. Meanwhile, SVP, Technical Operations Henderson Mary Elizabeth sold 1410.0 shares on Sep 06 ’24.
